Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san diego blog main
9
×
biotech
boston blog main
boston top stories
national top stories
new york blog main
san diego top stories
san francisco blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
amgen
cancer
dyne therapeutics
fda
merck
purdue pharma
vertex pharmaceuticals
biotech ipos
boston
bristol-myers squibb
diagnostics
europe blog main
What
drug
9
×
bio
roundup
therapeutics
brings
cancer
data
dyne
dyne’s
fda
genetic
immunotherapy
ipo
long
market
medicines
muscle
new
patients
plan
pricing
rare
acquisitions
advanced
advantages
agency
ago
aimmune
allergy
anathema
approval
approved
arrival
awaited
award
awarded
bar
biggest
biotechs
build
Language
unset
9
×
Current search:
drug
×
unset
×
" san diego blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)